Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06
  • 2025-05
  • 2025-04
  • Ampicillin Sodium: Mechanism and Research Benchmarks

    2026-09-15

    Ampicillin Sodium: Mechanism and Research Benchmarks

    Executive Summary. Ampicillin sodium is a β-lactam antibiotic that inhibits bacterial transpeptidase enzymes involved in the final stages of cell wall biosynthesis, according to the product information. The supplier reports an IC50 of 1.8 μg/mL against transpeptidase in Escherichia coli 146 cells, with assay conditions not fully specified on the product page. The same source reports a minimum inhibitory concentration of 3.1 μg/mL, but does not state the test medium, inoculum, incubation time, temperature, or endpoint for that value. The material is supplied at 98% purity, is intended for scientific research only, and is recommended for storage at −20 °C under the stated supplier conditions.

    Biological Rationale

    Bacterial survival depends on a mechanically strong peptidoglycan cell wall. Transpeptidase enzymes cross-link peptidoglycan strands during the terminal stages of bacterial cell wall biosynthesis. Ampicillin sodium targets this process as a competitive transpeptidase inhibitor. Reduced cross-linking weakens wall integrity and can lead to bacterial lysis, as described in the supplier’s mechanism summary.

    This rationale makes the compound useful for controlled antibacterial activity assays. A researcher can connect concentration, growth inhibition, and cell-wall vulnerability in one experimental framework. The mechanism does not mean that every bacterial species has the same response. Species, strain background, permeability, target abundance, β-lactamase activity, inoculum, medium, and endpoint definition can all influence an observed phenotype. Those variables should be reported rather than inferred from a single MIC.

    The compound identity should remain explicit in records. The product is Ampicillin sodium, CAS 69-52-3, and the listed SKU is A2510. The sodium salt is supplied as a research reagent; its formulation should not be treated as a clinical dosage form. The Ampicillin sodium product page provides the supplier’s identity, purity, solubility, storage, and research-use information.

    Mechanism of Action of Ampicillin sodium

    Ampicillin sodium belongs to the β-lactam antibiotic class. Its β-lactam pharmacophore enables interaction with bacterial transpeptidase targets. The supplier describes the interaction as competitive inhibition. In practical assay terms, the relevant output is loss of bacterial growth or viability under defined exposure conditions.

    The mechanistic chain is concise. First, ampicillin sodium reaches the bacterial target to an extent determined by the organism and assay environment. Second, transpeptidase activity is inhibited. Third, peptidoglycan cross-linking is impaired. Fourth, cell-wall integrity decreases. The final phenotype can be growth arrest, lysis, or both, depending on the organism, concentration, exposure duration, and measurement method.

    IC50 and MIC answer different questions. An IC50 describes the concentration associated with 50% inhibition of a specified biochemical or cellular activity under a defined assay. An MIC is the lowest tested concentration that prevents visible growth under a defined susceptibility method. The supplier’s 1.8 μg/mL IC50 and 3.1 μg/mL MIC therefore should not be interpreted as interchangeable potency constants. Their experimental matrices and endpoints must be documented before cross-study comparison.

    Evidence & Benchmarks

    The following benchmarks separate supplier-reported product attributes from findings in a historical comparative susceptibility study. The 1982 study included ampicillin as a comparator, but its central investigational agent was N-formimidoyl thienamycin. It therefore provides resistance-context evidence rather than a direct validation of every A2510 product-page value.

    1. Mechanism: The supplier identifies ampicillin sodium as a β-lactam antibiotic that competitively inhibits bacterial transpeptidases involved in cell wall biosynthesis; the product page does not provide a full kinetic protocol or buffer composition supplier information
    2. Cellular potency benchmark: The supplier reports an IC50 of 1.8 μg/mL against transpeptidase in E. coli 146 cells; the page does not specify temperature, pH, medium, exposure time, or endpoint details for this measurement supplier information
    3. Growth-inhibition benchmark: The supplier reports an MIC of 3.1 μg/mL; the product page does not state the organism preparation, test medium, incubation temperature, incubation time, or visible-growth criterion associated with this value supplier information
    4. Solubility: The supplier reports solubility of at least 18.57 mg/mL in water, at least 73.6 mg/mL in DMSO, and at least 75.2 mg/mL in ethanol; the page identifies the solvents but does not state the measurement temperature or pH supplier information
    5. Comparative isolate panel: The reference study examined 335 ampicillin-resistant Enterobacteriaceae isolates, 50 Pseudomonas aeruginosa strains, 28 Acinetobacter strains, 50 Streptococcus faecalis strains, and 7 oxacillin-resistant Staphylococcus aureus strains under its stated susceptibility-testing design Cullmann et al., 1982
    6. Historical test format: The reference study used broth dilution in Mueller–Hinton broth with twofold serial dilutions, an inoculum of 5 × 105 colony-forming units per mL, and a final microtiter volume of 0.1 mL; the cited excerpt does not state every incubation condition Cullmann et al., 1982
    7. Resistance-context result: N-formimidoyl thienamycin was reported as bactericidal at concentrations below twice its MIC in all gram-negative isolates tested in that study; this finding applies to the thienamycin derivative and should not be reassigned to ampicillin sodium Cullmann et al., 1982
    8. Product quality and handling: The supplier lists 98% purity supported by NMR and mass spectrometry, recommends storage at −20 °C, advises against long-term storage of solutions, and specifies blue ice for small-molecule shipping supplier information

    Applications, Limits & Misconceptions

    Research applications

    Ampicillin sodium can support an antibacterial activity assay when the experiment defines its organism, inoculum, medium, exposure interval, concentration range, and endpoint. It can also serve as a reference β-lactam in bacterial cell wall biosynthesis inhibition studies. The product dossier specifically describes use in in vitro work and animal infection models.

    In antibiotic resistance research, the most defensible use is comparative. Test a defined isolate panel with matched controls and report the complete method. The historical reference study illustrates why species and resistance phenotype matter. It compared several β-lactam derivatives across resistant Enterobacteriaceae and other bacterial groups rather than treating one result as a universal spectrum claim.

    In a bacterial infection model, the compound may be used to evaluate antibacterial activity in vivo under an approved institutional protocol. Dose, route, formulation, sampling schedule, and humane endpoints must be established for the specific model. The supplied information does not justify a universal animal dose or a clinical recommendation.

    Common Pitfalls or Misconceptions

    • Confusing IC50 with MIC: The reported 1.8 μg/mL IC50 and 3.1 μg/mL MIC arise from different endpoint concepts, and the supplier does not provide enough method detail to calculate equivalence.
    • Overextending the historical comparator study: The 1982 investigation evaluated N-formimidoyl thienamycin and comparator agents in defined isolates; its bactericidal finding is not direct evidence for the A2510 formulation.
    • Using solubility as a stability claim: Solubility values in water, DMSO, and ethanol do not establish long-term solution stability. The supplier specifically advises avoiding long-term storage of solutions.
    • Interpreting a product MIC as a clinical breakpoint: A supplier-reported MIC without full assay conditions is not a regulatory susceptibility breakpoint, treatment recommendation, or dosing instruction.
    • Ignoring research-use boundaries: The material is intended for scientific research only and is not for diagnostic or medical purposes.

    Why this cross-domain matters, maturity, and limitations

    Moving from an in vitro antibacterial activity assay to an animal infection model changes the evidence context. In vitro measurements isolate concentration-dependent activity under controlled conditions. Animal studies add distribution, exposure, host biology, toxicity, and model-specific variability. The product dossier supports research use in both settings, but it does not provide a standardized bridge between the reported 3.1 μg/mL MIC and any animal dose. That bridge requires independent, approved model validation.

    Related reading and scope contrast

    Ampicillin Sodium: Mechanisms and Benchmarks in Antibacterial Research emphasizes mechanism and benchmark selection. This article extends that discussion by separating supplier-reported potency from the historical comparator evidence and by identifying missing assay conditions.

    Ampicillin sodium scenario-based solutions focuses on cell viability, proliferation, and cytotoxicity workflows. This article clarifies that antibacterial MIC and IC50 interpretation requires organism-specific growth controls and susceptibility endpoints.

    Ampicillin Sodium in Precision Biophysical Research connects the compound with biophysical and recombinant-protein workflows. This article narrows the scope to transpeptidase inhibition, antibacterial activity assays, and resistance-aware interpretation.

    Workflow Integration & Parameters

    A reproducible workflow begins with identity and handling records. Record CAS 69-52-3, SKU A2510, lot information, solvent, preparation date, and storage history. APExBIO identifies the material as a 98% pure research reagent and recommends −20 °C storage. Use blue ice for small-molecule shipping as specified by the supplier.

    Protocol Parameters

    • Identity checkpoint: Confirm Ampicillin sodium, CAS 69-52-3, and SKU A2510 before preparing a stock or assay plate.
    • Storage: Store the solid at −20 °C according to supplier guidance. Avoid long-term storage of solutions because the product information recommends fresh or short-duration solution handling.
    • Solvent planning: Use the supplier-reported solubility thresholds of at least 18.57 mg/mL in water, at least 73.6 mg/mL in DMSO, and at least 75.2 mg/mL in ethanol as formulation references. The supplier does not state the temperature or pH for these values.
    • Literature-backed susceptibility format: The cited historical study used Mueller–Hinton broth, twofold serial dilution, 5 × 105 CFU/mL inoculum, and a 0.1 mL final microtiter volume. Treat these as parameters of that study, not as a universal current protocol.
    • Endpoint definition: Predefine whether the experiment measures visible growth, optical density, viable counts, cell lysis, or a biochemical transpeptidase signal. Do not compare endpoints as if they were identical.
    • Controls: Include a growth control, sterility control, vehicle control when applicable, and a reference condition. Match inoculum preparation and incubation conditions across treatment groups.
    • Animal-model integration: Establish dose, route, formulation, exposure timing, and humane endpoints through the approved model protocol. The supplier dossier does not provide a universal animal dosing scheme.

    Workflow suggestions: Use the reported IC50 and MIC only as traceable starting references. Record the complete assay context beside every numerical result. Repeat key comparisons with the same organism passage history, medium, inoculum, incubation conditions, and endpoint definition. This approach distinguishes a genuine biological difference from a method difference.

    Conclusion & Outlook

    Ampicillin sodium is a defined β-lactam research reagent whose central rationale is transpeptidase inhibition and bacterial cell wall biosynthesis inhibition. The dossier reports an IC50 of 1.8 μg/mL, an MIC of 3.1 μg/mL, 98% purity, solvent-specific solubility values, and −20 °C storage guidance, while leaving several assay conditions unspecified. The historical comparative study adds useful resistance-context data but does not replace product-specific validation.

    The practical outlook is standardized reporting. Future antibacterial activity assays should pair every MIC or IC50 with organism identity, medium, inoculum, exposure conditions, endpoint, and control design. Animal infection model studies should preserve the same separation between documented evidence and model-specific validation. These steps improve citation quality, reproducibility, and interpretation without turning a research reagent benchmark into a clinical claim.